<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390334</url>
  </required_header>
  <id_info>
    <org_study_id>ID-078-120</org_study_id>
    <secondary_id>2020-000653-27</secondary_id>
    <nct_id>NCT04390334</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.</brief_title>
  <official_title>Single-center, Randomized, Open-label Study to Investigate the Effect of Single-dose Famotidine and Multiple-dose Efavirenz on the Pharmacokinetics of Daridorexant in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy male subjects to investigate the effect of famotidine and efavirenz on the
      way the body takes up, distributes, and gets rid of daridorexant.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">July 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>4 treatment arms in 2 sequences, ABCD or BACD.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameter of daridorexant: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Various time points during Treatment A through D (Total duration: up to 3 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of daridorexant: Time to reach Cmax (tmax)</measure>
    <time_frame>Various time points during Treatment A through D (Total duration: up to 3 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of daridorexant: AUC from zero to infinity (AUC0-inf)</measure>
    <time_frame>Various time points during Treatment A through D (Total duration: up to 3 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of daridorexant: AUC from zero to 48 hours (AUC0-48)</measure>
    <time_frame>Various time points during Treatment A through D (Total duration: up to 3 weeks).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of daridorexant: Terminal elimination half-life (tÂ½)</measure>
    <time_frame>Various time points during Treatment A through D (Total duration: up to 3 weeks).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent (S)AEs</measure>
    <time_frame>Up to EOP for each of the Periods 1 to 3 and up to EOS for Period 4 (Total duration: up to 3 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: Daridorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 50 mg daridorexant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Famotidine &amp; daridorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 40 mg famotidine followed 3 h later by a single dose of 50 mg daridorexant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg efavirenz once daily in the evening from Day 5 to Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Daridorexant &amp; efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 50 mg daridorexant in the morning of Day 15 followed by a single dose of 600 mg efavirenz in the evening of Days 15 and 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daridorexant</intervention_name>
    <description>Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.</description>
    <arm_group_label>Treatment A: Daridorexant</arm_group_label>
    <arm_group_label>Treatment B: Famotidine &amp; daridorexant</arm_group_label>
    <arm_group_label>Treatment D: Daridorexant &amp; efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.</description>
    <arm_group_label>Treatment B: Famotidine &amp; daridorexant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.</description>
    <arm_group_label>Treatment C: Efavirenz</arm_group_label>
    <arm_group_label>Treatment D: Daridorexant &amp; efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in a language understandable to the subject prior to any
             study-mandated procedure.

          -  Healthy male subjects aged between 18 and 45 years (inclusive) at Screening.

        Exclusion Criteria:

          -  Clinically relevant findings on the physical examination at Screening.

          -  Clinically relevant abnormalities on 12-lead ECG, measured after at least 5 min in a
             supine position at Screening.

          -  Clinically relevant findings in clinical laboratory tests (hematology, clinical
             chemistry) at Screening and on Day -1.

          -  History of major medical or surgical disorders which, in the opinion of the
             investigator, are likely to interfere with the absorption, distribution, metabolism,
             or excretion of the study treatment(s) (appendectomy and herniotomy allowed,
             cholecystectomy not allowed).

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.

          -  Moderate or severe renal insufficiency (creatinine clearance &lt; 60 mL/min calculated
             with the Cockcroft Gault formula) at Screening.

          -  Total bilirubin &gt; 1.5 x Upper Limit of Normal at Screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

